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Abstract
Background: Pseudohypoparathyroidism (PHP) is caused by (epi)genetic defects in the imprinted GNAS cluster.
Current classification of PHP patients is hampered by clinical and molecular diagnostic overlaps. The European
Consortium for the study of PHP designed a genome-wide methylation study to improve molecular diagnosis.
Methods: The HumanMethylation 450K BeadChip was used to analyze genome-wide methylation in 24 PHP
patients with parathyroid hormone resistance and 20 age- and gender-matched controls. Patients were previously
diagnosed with GNAS-specific differentially methylated regions (DMRs) and include 6 patients with known STX16
deletion (PHPΔstx16) and 18 without deletion (PHPneg).
Results: The array demonstrated that PHP patients do not show DNA methylation differences at the whole-
genome level. Unsupervised clustering of GNAS-specific DMRs divides PHPΔstx16 versus PHPneg patients. Interestingly,
in contrast to the notion that all PHP patients share methylation defects in the A/B DMR while only PHPΔstx16
patients have normal NESP, GNAS-AS1 and XL methylation, we found a novel DMR (named GNAS-AS2) in the GNAS-
AS1 region that is significantly different in both PHPΔstx16 and PHPneg, as validated by Sequenom EpiTYPER in a
larger PHP cohort. The analysis of 58 DMRs revealed that 8/18 PHPneg and 1/6 PHPΔstx16 patients have multi-locus
methylation defects. Validation was performed for FANCC and SVOPL DMRs.
Conclusions: This is the first genome-wide methylation study for PHP patients that confirmed that GNAS is the
most significant DMR, and the presence of STX16 deletion divides PHP patients in two groups. Moreover, a novel
GNAS-AS2 DMR affects all PHP patients, and PHP patients seem sensitive to multi-locus methylation defects.
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Background
Genomic imprinting is a parent-of-origin dependent
gene expression that is essential for mammalian develop-
ment. A mechanism underlying allele-specific expression
is DNA methylation. The addition of a methyl group to
DNA cytosine nucleotides at CpG sites can occur in an
allele-specific manner, and allele-specific methylation in
imprint control regions (referred to as differentially
methylated regions (DMRs)) is associated with parent-of-
origin dependent gene expression. Imprinting disorders
are a group of rare diseases affecting growth, devel-
opment, and metabolism that are associated with
(epi)genetic disruption of imprinting genes [1]. Pseu-
dohypoparathyroidism (PHP) is a rare endocrine dis-
order that can be caused by genetic or epigenetic
alterations in the imprinted cluster GNAS localized
on chromosome 20q13.3 [2]. The human GNAS locus
harbors four DMRs encompassing the promoters of
four alternative transcripts: exon A/B (GNAS-A/B: TSS
DMR=A/B), GNAS antisense (GNAS-AS1: TSS DMR =
AS1), extra-large stimulatory G protein (GNAS-XL: Ex1
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DMR=XL), and neuroendocrine secretory protein 55
(GNAS-NESP: TSS DMR=NESP) (Fig. 1a) [3]. PHP type I
(PHP1A and PHP1B) patients are characterized by end-
organ resistance to the action of the parathyroid hormone
(PTH), which leads to hypocalcemia, hyperphosphatemia,
and elevated levels of PTH in the absence of vitamin D
deficiency. They often also have thyroid-stimulating hor-
mone (TSH) resistance [2, 3]. PHP1A patients have in
addition to hormone resistance clinical features collect-
ively referred to as Albright’s hereditary osteodystrophy
(AHO) that include brachydactyly, short stature, and
round face; they may also present with obesity, subcutane-
ous ossifications, mental retardation, and behavior prob-
lems [4, 5]. PHP1A is caused by heterozygous maternally
inherited inactivating mutations in the coding sequence of
Gsα (exons 1 to 13 of GNAS) [2, 3, 6]. On the other hand,
paternally inherited inactivating mutations lead to pseu-
dopseudohypoparathyroidism (PPHP), characterized by
AHO features but without hormone resistance [2, 3, 6].
Most patients affected with the PHP1B form of the dis-
ease exhibit mainly PTH resistance and subclinical
TSH resistance and do not have AHO features. In some
cases however, typical brachydactyly, severe obesity [7],
and congenital hypothyroidism [8, 9] have been de-
scribed in PHP1B patients highlighting the overlap be-
tween PHP1A and PHP1B. All PHP1B patients have
methylation abnormalities in the GNAS cluster with
loss of imprinting at the A/B DMR [6]. The familial
form of PHP1B (often referred to as autosomal domin-
ant AD-PHP1B) is typically associated with microdele-
tions in the STX16 region located upstream of the
GNAS cluster [10–13] and less frequently with deletion
removing the NESP DMR [14]. On the other hand,
sporadic PHP1B patients have broad GNAS methylation
defects that involve all four GNAS DMRs without a
known underlying genetic cause [2, 3, 6].
However, from recent data, it becomes clear this ori-
ginal PHP classification is no longer accurate for the fol-
lowing four reasons: (i) broad GNAS methylation defects
were also found for PHP1B patients with an AHO
phenotype [7, 15–17], (ii) the degree of the methylation
defect seems not to correlate with the disease severity
[18], (iii) reduced Gsα activity is no longer exclusive for
PHP1A with inactivating mutations but recently also
was described for PHP patients with epigenetic defects
[19, 20], and (iv) partial GNAS methylation defects have
Fig. 1 Human GNAS cluster. a Schematic diagram of the human GNAS cluster with DMRs A/B, XL, GNAS-AS, and NESP and the upstream STX16
gene region. The arrows show initiation and direction of transcription for maternal (mat)- and paternal (pat)-derived transcripts. b Overview of the
different GNAS methylation studies that were performed for 24 PHP patients in this study using the HM450k and Sequenom EpiYTPER and previously,
by five different European centers using the specified techniques and loci. c Detailed schematic representation of the four GNAS DMRs investigated by
the different European laboratories and the consortium. Nucleotide positions are indicated according to NCBI build 37/hg19
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been described [21]. Moreover, as shown for other im-
printing disorders, such as Silver-Russell or Beckwith-
Wiedemann syndrome, also some PHP1B patients were
shown to have multi-locus imprinting defects as studied
by a targeted approach that comprised known imprinted
loci [22–24]. Therefore, there is a strong need to im-
prove the current classification of PHP patients that
might be feasible based on more detailed (epi)genetic or
clinical data using larger patient cohorts analyzed with
more powerful techniques. The European Consortium
for the study of PHP (EuroPHP) designed the present
genome-wide methylation study to gain insight in epi-
genetic profiles that might improve an epigenetic-based
classification. We have analyzed the methylomes of 24
previously diagnosed PHP patients with GNAS epigen-
etic defects recruited from five European centers. This
sample set includes 6 patients with the STX16 3-kb re-
current microdeletion (PHPΔstx16) [11] and 18 without
any identified deletion within the GNAS locus (PHPneg).
The following analyses were performed: (i) changes in
DNA methylation at the genome-wide level, (ii) un-
supervised cluster analysis for the GNAS locus and com-
parisons with previous GNAS methylation data used for
PHP diagnosis, and (iii) detailed DNA quantification
analysis for other imprinted DMRs. DNA methylation
data were validated with the Sequenom EpiTYPER for
additional PHP patients with PTH resistance and proven
epigenetic defects.
Results
Genome-wide DNA methylation analysis for PHP patients
The Illumina Infinium HumanMethylation 450K Bead-
Chip (HM450k) was used to determine genome-wide
DNA methylation profiles in 24 PHP patients and 20
age- and gender-matched healthy controls. Table 1 pre-
sents the clinical characteristics of the PHP patients that
all have PTH resistance and hypocalcemia. Mild AHO
features were only present in patients 8, 10, 13, 15, and
20. All 24 PHP patients were previously diagnosed with
a GNAS epigenetic defect using different methodologies
(Fig. 1b, c), and methylation values for the different
GNAS DMRs obtained by these assays are shown in
Table 1. We have included 6 PHP patients with a dele-
tion of the STX16 region upstream of GNAS and hypo-
methylation of the A/B DMR only (referred to as
PHPΔstx16) and 18 PHP patients without the deletion
and full or partial methylation defects in A/B, XL, AS1,
and NESP DMRs (referred to as PHPneg) (Table 1). Hier-
archical cluster analysis of all CpGs according to the dif-
ferent subtypes PHPΔstx16, PHPneg, or control (Fig. 2a)
and unsupervised hierarchical clustering analysis of the
data (Fig. 2b) showed that the samples are clustered irre-
spective of the subgroup, suggesting that there are no
subgroup differences at whole-genome level. To further
exclude a global methylation defect in PHP patients, we
also analyzed the methylation of DNA repetitive ele-
ments (LINE-1 and LINE-2) that again showed no differ-
ences between patients and controls (data not shown).
GNAS methylation analysis based on HM450k data for
PHP patients
The methylation values for all CpGs located within the
GNAS cluster were extracted from data obtained from
the genome-wide methylation analysis (Additional file 1:
Table S1). The HM450k contains probes mapping to
four regions that cover the four GNAS DMRs as speci-
fied by red boxes in Fig. 1c (referred to as A/B, XL, AS1,
and NESP). These regions are larger but overlap with
the regions that were previously investigated by five
European centers that have used different technologies
including MS-MLPA, Sequenom EpiTYPER, or pyrose-
quencing to quantify the methylation of the GNAS
DMRs for the 24 PHP patients (see Fig. 1c for the loca-
tion of the studied regions and methodologies and
Table 1 for the results for each patient). Unsupervised
hierarchical cluster analysis of GNAS methylation data
obtained from the HM450k for the 24 PHP patients di-
vided these patients in 2 groups according to the pres-
ence/absence of STX16 deletion (PHPΔstx16 versus
PHPneg) (Fig. 3). As known in literature [2, 3] and con-
firming the previous diagnosis that was made by the 5
laboratories, PHPΔstx16 only showed hypomethylation of
DMR A/B while PHPneg patients had abnormal methyla-
tion for all 4 GNAS DMRs. However, 2 PHPneg patients
(23 and 24) were clustered closer to the healthy control
population having normal methylation values for the all
GNAS DMRs (Table 1 and Fig. 3). These patients were
previously identified with a “partial” GNAS methylation
defect using MS-MLPA and pyrosequencing respect-
ively. After analyzing the separate CpGs from the
HM450k, no significant differences were found com-
pared to the control population (separated CpGs are vi-
sualized in Fig. 3). At the individual probe level, we
noticed that both patients were mosaic and patient 23
was slightly more hypomethylated than patient 24.
Interestingly, a smaller region we referred to as AS2
within the AS1 amplicon had significantly lower methy-
lation values for both PHPΔstx16 and PHPneg patients
compared to the controls (Fig. 3 and Table 1). This AS2
region does not overlap with amplicons that were previ-
ously studied for the AS region by MS-MLPA, Seque-
nom EpiTYPER, or pyrosequencing by the different
laboratories (Fig. 1b, c and Additional file 2: Figure S1).
The AS2 region is separated from XL by a hypermethy-
lated region (Fig. 3). To confirm AS2 hypomethylation,
a validation study was developed using the Sequenom
EpiTYPER to quantify methylation in the AS2 region
(Additional file 2: Figure S1) in 42 PHP patients with
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Table 1 Clinical and molecular characteristics of the PHP patients enrolled in the genome-wide DNA methylation study
1. Clinical characteristics 2. Initial diagnostic screening 3. HM450k
Patient Gender PTH-res TSH-res Ca ↓ P ↑ OS BD Additional features STX16 LAB Label NESP AS XL A/B NESP AS1 AS2 XL A/B
1 F Yes Yes Yes Yes No No Two café-au-lait spots, autoimmune
thyroiditis
4 Full PHP1B—broad 94 7 27 3 90** 10** 8** 34* 13**
2* M Yes Yes Yes Yes No No 3 Full PHP1B—broad 80 7 8 2 89** 10** 8** 6** 12**
3 M Yes Yes Yes No No Von Willebrand disease 5 Full PHP1B—broad 88 4 6 0 88** 10** 8** 7** 13**
4* M Yes No Yes Yes No No 1 Full PHP1B—broad 92 8 7 89** 10** 8** 7** 13**
5* M Yes No Yes Yes No No 3 Full PHP1B—broad 82 7 8 2 89** 9** 8** 7** 12**
6 F Yes No Yes Yes No No 1 Full PHP1B—broad 92 10 9 89** 9** 7** 5** 12**
7 M Yes No Yes Yes No No Bilateral cryptorchidism, osteopenia
of hands, behavior problems
4 Full PHP1B—broad 95 5 4 3 89** 9** 8** 5** 12**
8* F Yes Yes No No Yes 5 Full PHP1B—broad 90 3 4 0 89** 10** 8** 6** 12**
9 F Yes Yes Yes No No Enchondromatosis 5 Partial PHP1B—broad 83 23 34 33 63 27 23 24* 35
10 F Yes No Yes Yes No Yes Exostosis 4 Partial PHP1B—broad 84 20 24 13 75* 22* 16** 33* 31
11 F Yes 5 Partial PHP1B—broad 80 10 27 14 78* 23* 19* 34* 28
12* M Yes Yes Yes No No No Severe hypertension with organ damage,
hypercalciuria
3 Full PHP1B—broad 77 8 8 3 75* 12** 8** 7** 17**
13* F Yes Yes Yes Yes No Yes 3 Partial PHP1A—broad 76 8 7 5 73* 15** 9** 5** 21*
14* M Yes Yes Yes No No No 3 Partial PHP1B—broad 80 10 19 29 76* 19** 13** 30* 21*
15 F Yes Yes Yes Yes Yes No Langerhans cell histiocytosis, neonatal
hydrocephaly, sessile exostosis
4 Partial PHP1A—broad 86 18 18 7 81** 18** 15** 32* 21*
16 F Yes Yes Yes Yes No No Fahr’s syndrome (calcifications of basal
ganglia), autoimmune thyroiditis
4 Partial PHP1B—broad 91 12 30 7 85** 17** 16** 43 21*
17 F Yes No Yes No No No ΔSTX16 3 PHP1B—A/B only 42 36 44 6 46 36 16** 45 14**
18* F Yes Yes No No ΔSTX16 2 PHP1B—A/B only - - - 4 50 37 14** 47 14**
19 M Yes Yes Yes Yes Yes No Calcifications of basal ganglia ΔSTX16 4 PHP1B—A/B only 49 42 52 3 50 41 18** 48 15**
20 F Yes No Yes Yes No Yes ΔSTX16 1 PHP1B—A/B only 39 - 36 10 50 40 16** 50 15**
21 M Yes Yes No Yes ΔSTX16 2 PHP1B—A/B only - - - 4 52 41 16** 51 13**
22 M Yes No Yes No No No ΔSTX16 1 PHP1B—A/B only 29 - 38 14 53 42 14** 51 14**
23* F Yes No Yes Yes No No 3 Partial PHP1B—broad 54 26 30 7 55 36 26 40 41
24 M Yes No Yes Yes No No Severe osteopenia without
ossifications
5 Partial PHP1B—broad 70 35 46 44 57 39 34 41 43
50 ± 7 46 ± 7 39 ± 7 50 ± 4 51 ± 9
From left to right: (1) clinical characteristics; (2) mean methylation values of GNAS studies that were performed previously by five different European centers as described in Fig. 1; and (3) mean methylation values of
GNAS investigated with HM450k. Ordering of the patients according to unsupervised hierarchical clustering of GNAS methylation investigated with HM450k. Patients* have methylation changes at imprinted genes
other than GNAS. Methylation values are presented as percentage. Mean ± SD of the 20 controls from the HM450k array is shown below the HM450k columns
BD brachydactyly, Ca calcium, F female, LAB laboratory of initial diagnostic screening, annotation as shown in Fig. 1, M male, OS heterotopic ossifications, P phosphate, PTH-res parathyroid hormone resistance, TSH-res
thyroid-stimulating hormone resistance, ΔSTX16 patients with underlying STX16 deletion
*Methylation < or >3SD outside the mean of the controls









PTH resistance that were previously diagnosed with a
GNAS epimutation and 20 age- and gender-matched
healthy controls. These 42 PHP patients include 20
PHPΔstx16 and 22 PHPneg patients, of which 3 patients
in each group were also analyzed by HM450k array
(Additional file 1: Table S2). The 22 PHPneg comprise
20 PHP1B with full or partial broad GNAS methylation
defect and 2 PHP1B patients with isolated A/B methy-
lation defect but having no STX16 deletion (Additional
file 1: Table S3). Significant AS2 hypomethylation (P
value <0.0001) was detected for both PHPΔstx16 and
PHPneg patient groups compared to controls (Fig. 4 and
Additional file 1: Table S3). No significant difference in
AS2 methylation was found between PHPΔstx16 and
PHPneg patients with mean methylation values of 10 %
(95 % confidence interval (CI) 7–13 %) versus 8 %
(95 % CI 5–11 %), respectively. This suggests that the
imprinting defect for this interval is not determined by
the STX16 deletion and is specific for PHP1B. To inves-
tigate if AS2 hypomethylation changed XL expression,
we performed GNAS versus XL messenger RNA
(mRNA) expression studies using total blood mRNA
from a PHPneg patient and control heterozygous for
GNAS SNP (rs7121), but we could not detect XL ex-
pression in blood cells.
Methylation studies of other imprinted genes for PHP
patients
As multi-locus abnormalities have also been described
for PHP1B patients [23], we analyzed the methylation
values for all CpGs located within 58 imprinted DMRs
for humans that are covered by the HM450k (Additional
file 1: Table S4 and S5). In addition to methylation ab-
normalities for the 4 GNAS DMRs, we found multi-
locus methylation defects in 8 PHPneg and 1 PHPΔstx16
patients (Fig. 5). Abnormal methylation was found for
19 of the 58 human imprinted DMRs, and this included
significant hypomethylation for PPIEL:Ex1-DMR, DIRA-
S3:Ex2-DMR, DIRAS3:TSS-DMR, JAKMIP1, NAP1L5:TSS-
DMR, FAM50B:TSS-DMR, SVOPL, FANCC:Int1-DMR,
SNRPN:alt-TSS-DMR, IGF1R:Int2-DMR, LOC100130522/
PARD6G-AS1, WRB:alt-TSS-DMR, and NHP2L1:alt-TSS-
DMR and significant hypermethylation for ZBDF2/
GPR1:IG-DMR, PEG13:TSS-DMR, RB1:Int2-DMR, SNRPN
intragenic CpG40, SNRPN_2, and SNRPN_3. ZBDF2/
GPR1:IG-DMR hypermethylation is likely due to GPR1-
AS:TSS-DMR hypomethylation. The GPR1-AS:TSS-DMR
is not included in our screening, as it acquires immediate
biparental methylation following implantation; therefore,
we can only infer loss of methylation due to hyperme-
thylation of ZBDF2 [25]. The clinical phenotype of the
Fig. 2 Whole-genome methylation in PHP patients versus controls. Methylation values are extracted from data obtained with the HM450k. a
Clustering according to different subgroups. b Unsupervised hierarchical clustering analysis of the subgroups. Control controls, PHPΔSTX16 patients
with underlying STX16 deletion, PHP patients without known genetic deletion. Heatmaps represent 3575 randomly selected CpGs (1 % total CpGs)
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patients with multi-locus methylation abnormalities
was not different from the PHP patients with GNAS-
specific epimutations (Table 1).
To confirm the findings of multi-locus abnormalities,
we performed a validation study using the Sequenom
EpiTYPER for 26 PHP patients and 12 healthy controls.
We have selected FANCC and SVOPL as hypomethyla-
tion was seen in 3 and 7 PHP patients, respectively. We
also validated the methylation of WDR27 amplicon as
negative control. The 26 PHP patients included 5
PHPΔstx16 and 21 PHPneg patients; 3 patients of each
group were also analyzed by HM450k (Additional file 1:
Table S2). Eight patients had multi-locus methylation
abnormalities (Fig. 6 and Additional file 1: Table S6).
The most significant methylation difference was found
for SVOPL in three PHPneg patients.
Discussion
Genome-wide studies to identify genetic alterations have
successfully entered the field of rare diseases [26]. Simi-
lar attempts to elucidate the epigenome are expected to
Fig. 3 Unsupervised hierarchical clustering of GNAS methylation in PHP patients. Methylation values of the individual CpGs of the four GNAS DMRs are
extracted from data obtained with the HM450k. Green and red represent 0 and 1 methylation, respectively. The arrows show the different GNAS transcripts
Fig. 4 Scatter plot of NESP-AS2 methylation in PHP patients and
controls. Methylation values are obtained with the Sequenom
EpiTYPER. Horizontal bars indicate the mean and SD of the group.
PHP patients are separated according to underlying STX16 deletion
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improve our limited knowledge about imprinting disor-
ders (IDs). There has been a revolution in DNA methy-
lation analysis technology over the past decade as
genome-wide and entire methylomes can be character-
ized at single-base-pair resolution [27]. Their implemen-
tation to study IDs has only just started. A custom
Illumina GoldenGate array targeting 27 imprinted DMRs
has been used to study 65 patients with an ID (that in-
clude Beckwith-Wiedemann syndrome (BWS), transient
neonatal diabetes mellitus (TNDM), PHP1B, Silver-
Russell syndrome (SRS), Angelman syndrome (AS), and
Prader-Willi syndrome (PWS)) and found multi-locus
hypomethylation in patients with BWS, SRS, TNDM,
and PHP1B, but not in AS and PWS [22]. Two studies
have used the HM450k array to quantify genome-
wide DNA methylation for BWS and TNDM [28] or
SRS patients [29] and concluded that multiple and
even novel imprinted genes were abnormally methyl-
ated in IDs.
Here, we have studied DNA methylation at about
485,000 CpGs genome-wide in 24 PHP patients with
proven but different types of GNAS epimutations. The
methylomes analyzed for 58 imprinted DMRs revealed
in addition to the expected GNAS methylation defect,
also a multi-locus methylation abnormality in 9 of the
24 patients for 19 other imprinted DMRs that were not
previously known for these PHP cases. However, patients
did not share a common pattern for these multi-locus
methylation abnormalities, and there was a high variabil-
ity in the degree of methylation difference and the num-
ber of amplicons per patient that were abnormally
methylated. A validation study with the EpiTYPER for
Fig. 5 Heatmap showing methylation of known imprinted genes in PHP patients. Methylation values of the genes are extracted from data obtained
with the HM450k. Dark green and red respresent −3SD and +3SD, respectively, of the mean as determined in 20 controls. Lighter green and red
represent additional cut-offs for absolute methylation <0.20 and >0.80. Patients* have multi-locus methylation abnormalities. PHPΔSTX16 patients with
underlying STX16 deletion
Rochtus et al. Clinical Epigenetics  (2016) 8:10 Page 7 of 12
the most common abnormally methylated DMRs
FANCC and SVOPL indeed showed significant methyla-
tion differences in a replication cohort of PHP patients.
The FANCC and SVOPL DMRs are not well studied,
and further studies are needed to define the functional
relevance of these methylation changes. Though larger
cohorts are needed to be conclusive, based on results
from both the HM450k and the EpiTYPER study, it
seems that PHPneg patients are more sensitive to these
multi-locus defects compared to PHPΔstx16 patients.
Other studies that have used targeted approaches with a
limited number of known imprinted DMRs have also re-
ported multi-locus defects in PHP patients. Perez-
Nanclares et al. reported the first two PHP patients with
multi-locus hypomethylation; one patient at PEG1/
MEST and the other at GTL2 [24]. Court et al. identified
five PHP patients with hypomethylation at other
imprinted loci: PEG1/MEST, MCTS2, IGF2R, ZNF331,
L3MTBL1, and MEG3 [22]. Maupetit-Méhouas et al.
studied a larger cohort of 63 PHP patients for the
methylation pattern at eight imprinted loci and found
multi-locus imprinting defects for 4 PHP patients at
PEG1/MEST, L3MBTL1, and DLK1/GTL2 [23]. Though
in our PHP cohort we observe a higher rate of multi-
locus methylation defects (38 % of all patients), this is
probably due to the fact that more DMRs were studied,
but remarkably, most of these previously reported ab-
normal DMRs are also abnormal in our study. Docherty
et al. identified novel candidate imprinted genes in pa-
tients with imprinting disorders and multi-locus methy-
lation defects [28]; we identified hypomethylation of
three candidate regions (PPIEL:Ex1-DMR, WRB:alt-TSS-
DMR, and NHP2L1:alt-TSS-DMR) from this study in
our patients with PHP1B. The clinical relevance of these
regions has not yet been determined. It is possible that
these genes are common in most imprinting disorders.
Interestingly, we identified two patients with methylation
changes in the SNRPN DMRs. These two patients also
have hypomethylation of the novel candidate DMR
LOC100130522/PARD6G-AS1 [28]. Methylation changes
in SNRPN DMRs are associated with PWS and AS, but
these patients are very infrequent and moreover loss of
methylation of the SNRPN DMR is rarely described in
other imprinting disorders with multi-locus methylation
disturbances. It has only been observed in two patients
with SRS [30], two patients with BWS [22, 28], and one
patient with TNDM [28]. In accordance with previous
studies, our PHP patients with multi-locus methylation
defects do not show evidence for phenotype differences
with patients having only a GNAS methylation defect.
Further studies including biochemical analyses are ne-
cessary to confirm these findings. The patient with the
highest number of genes presenting with a methylation
defect has severe hypertension with organ damage but a
link with the methylation defect is not obvious. The
other patients with multi-locus methylation defects have
no additional clinical or molecular features. We identi-
fied five patients with simultaneous hypo- and hyperme-
thylation. This finding is consistent with the report of
Maupetit-Méhouas [23]. The epidominance hypothesis
suggests that the phenotype is determined by the most
strongly affected imprinted locus [23]. Patients with hy-
pomethylation of multiple imprinted loci have been as-
sociated with increased frequency of developmental
delay and congenital anomalies [31], but based on our
current study, we have no evidence for a clinical impact.
Of particular interest is the fact that methylation dis-
turbances at multiple imprinted loci are now described
in a subset of patients affected with different IDs, and
this could point to a common pathogenic mechanism
for IDs [32].
According to the original classification for PHP, we
have included PHP1B patients with A/B only and partial
or full broad methylation defects and PHP1A patients
with a broad partial methylation defect. During the last
years, it became clear for reasons specified in the intro-
duction that this classification is no longer accurate. All
CpGs from the genome-wide data within the GNAS
cluster were analyzed using unsupervised hierarchical
cluster analysis. This analysis divided our patients in two
groups seemingly only dependent on having the STX16
deletion or not (referred to as PHPΔstx16 and PHPneg).
The studied intervals cover the 4 DMRs in GNAS but
these loci are much larger compared to the amplicons
that were previously studied by the different labs that
have used MS-MLPA, Sequenom EpiTYPER or pyrose-
quencing (for details see Fig. 1). PHP1B patients 23 and
24 that were diagnosed by MS-MLPA and
Fig. 6 Scatter plot of FANCC and SVOPL methylations in PHP patients
and controls. Methylation values are obtained with the Sequenom
EpiTYPER. Bar indicates the mean of the group. PHP patients are
separated according to underlying STX16 deletion. Patients that were
investigated with the HM450k are indicated in blue
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pyrosequencing having a partial broad GNAS methyla-
tion defect are now clustered more closer to the control
group. The most intriguing finding is however the dis-
covery of a novel previously not described DMR (named
GNAS-AS2) in the GNAS cluster that was found hypo-
methylated for both PHPΔstx16 and PHPneg patients.
GNAS-AS2 is located within the large GNAS-AS1 region
and is actually located in the promoter region of the XL
exon 1 (Additional file 2: Figure S1) but is separated
from XL by a hypermethylated region. Many studies
have described that PHP1B patients with STX16 deletion
only have hypomethylation of the A/B DMR while the
DMRs XL, GNAS-AS1, and NESP are normal [10–13].
This is also the case for the present HM450k data except
for the CpGs that are located in the GNAS-AS2 re-
gion. GNAS-AS2 hypomethylation for both PHPΔstx16
and PHPneg patients was validated with the EpiTY-
PER. Only 1/24 (1 with partial PHP1B—broad) and 4/
42 PHP (3 with PHP1B—A/B only and 1 with partial
PHP1B—broad) patients had a normal GNAS-AS2
methylation based on HM450k and EpiTYPER data,
respectively. Methylation defects affecting the mater-
nal A/B DMR lead to the loss of Gsα expression in
renal proximal tubules and renal PTH resistance. It is
however not clear at this moment whether hypome-
thylation of the GNAS-AS2 DMR has a phenotype
impact or whether methylation studies of this region
can be useful for a better characterization of PHP pa-
tients. Further experiments are also needed to deter-
mine if loss of methylation of DMR GNAS-AS2
influences the expression of GNAS-XL.
Conclusions
We here present the first genome-wide methylation
study in different types of PHP. It seems that only the
presence of the STX16 deletion is of significant import-
ance to divide PHP in two groups of patients with sig-
nificantly different methylation profiles. Methylation
changes in other imprinted DMRs seem to be enriched
in especially PHPneg patients. We identified a novel
GNAS-AS2 DMR in the GNAS locus that is hypomethy-
lated in all PHP patients, independently from STX16 de-
letion. Further studies must be undertaken to unravel
the function and clinical impact of methylation changes
in the GNAS-AS2 region that in addition to the A/B




A total of 61 PHP patients were enrolled by 5 different
endocrinology centers from the European PHP Consor-
tium. The molecular diagnosis for PHP was performed
by each center using the methylation detection assay for
the GNAS DMRs as previously described with method-
ologies and the location of the studied amplicons in
Fig. 1 and Table 1 [21]. All PHP patients included in this
study have PTH resistance and were labeled with
PHP1A if an obvious AHO phenotype was present (only
brachydactyly and subcutaneous ossifications were no-
ticed, Table 1). Based on the genetic screening for
STX16 deletions and GNAS methylation screening, la-
boratories were asked to label the patients with the fol-
lowing: (i) STX16 deletion present or not, (ii) AB-only or
broad methylation defect, and (iii) full or partial methyla-
tion defect [21]. This resulted in the use of the following
labels (Table 1): PHP1B—A/B only, full PHP1B—broad,
partial PHP1B—broad and partial PHP1A—broad. These
terms are based on the original classification used for pa-
tients with PHP type I.
Table 1 presents the patients for the genome-wide
study and Additional file 1: Table S2 the patients for
the replication studies. The order of the patients in
Table 1 was determined by unsupervised cluster ana-
lysis of genome-wide data for only the GNAS locus.
The total number of PHP patients that were enrolled
for the HM450k array and Sequenom studies are speci-
fied in Additional file 1: Table S2. Shortly, the genome-
wide DNA methylation study was performed for 24
PHP patients and 20 age- and gender-matched healthy
controls (Table 1). Validation of NESP-AS2 was per-
formed for 42 PHP patients and 20 controls (Add-
itional file 1: Table S3). Validation of the methylation
levels of FANCC, SVOPL, and WDR27 was performed
in 26 PHP patients and 12 controls (Additional file 1:
Table S6).
Informed consent for methylation and genetic studies
was obtained from all participants and/or their legal
representatives after approval of these studies by local
Ethical Committees.
Genome-wide methylation profiling using the HM450k
array
Genomic DNA was extracted from leukocytes using
standard techniques and bisulfite converted using the
EZ DNA methylation kit (Zymo Research, Irvine CA)
as previously described [33]. The array was performed
by the Genome Centre (Bart’s and the London School
of Medicine and Dentistry, Londen, UK) on the
HumanMethylation 450K BeadChip (Illumina) using
manufacturer’s reagents and protocols. An identical
control sample was assigned to each batch and samples
were distributed randomly to control for batch effects.
The correlation for the internal quality control was
high (>0.99). The methylation level (β value) was calcu-
lated using the Methylation Module of BeadStudio
software.
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HM450k data filtering and genome-wide analysis
After normalization of the data using GenomeStudio
software, data were analyzed using a pipeline devel-
oped within the R statistical analysis environment
(http://www.r-project.org, Bioconductor, Seattle, USA).
Before analyzing the data, we excluded possible
sources of technical bias. Probes with a high detection
value (p > 0.01) in more than 10 % of the samples
(644 probes) and probes containing any missing
values (13,194 probes) were removed, as well as non-
CpG and gender-matched probes. Finally, we excluded
probes as they contained SNPs present in >1 % of the
population and leukocyte-specific probes [34, 35]. In
total, we analyzed 355,105 probes for all DNA sam-
ples (73 % of probes). No statistical batch control was
required as all the cases and controls had been proc-
essed in the same time, and the correlation for the
quality control was high (>0.99). The mean methyla-
tion and standard deviation were determined for the
control population and individual samples. We did
not detect any differentially methylated DMRs be-
tween the 20 control samples. DNA samples from
imprinting syndrome patients were considered epimu-
tated if the methylation value for an imprinted DMR
differed was outside 3 standard deviations from the
20 control samples. Cluster analysis was performed
within the R statistical analysis environment.
HM450k data filtering for analysis of imprinted genes
We analyzed 58 imprinted DMRs that also included the
DMRs of the GNAS cluster (Additional file 1: Table S4).
The list was based on the known imprinted DMRs
from the consensus list from the European Network
of Human Congenital Imprinting Disorders (http://
www.imprinting-disorders.eu). In addition, we in-
cluded novel human imprinted DMRs from recent re-
search that combined whole-genome bisulfite sequencing
with HM450k to generate methylation profiles [36] as well
as four novel candidate DMRs (GLP2R, JAKMIP1,
LOC100130522/PARD6G-AS1, SVOPL) from research
using genome-wide methylation profiling with HM450k
in patients with multi-locus methylation defects [28].
These regions have not yet been further characterized
to determine SNP versus parental-origin methylation
and tissue profile. Some DMRs of the list are secondary
DMRs (i.e., DIRAS3:Ex2-DMR, all the SNRPN DMRs).
Validation of NESP-AS2 and FANCC, SVOPL, WDR27
methylation using the Sequenom EpiTYPER
Leukocyte DNA (1 μg) was subjected to bisulfite treat-
ment using the MethylDetector™ bisulfite modification
kit (Active Motif, Carlsbad CA, USA) as we described
[21, 33, 36–38]. The Sequenom MassARRAY (Seque-
nom, San Diego, CA, USA) was used for quantitative
DNA methylation analysis of the CpGs within the ampli-
cons of FANCC, SVOPL, and WDR27 using conditions
described. Long cycling incubation was applied to fur-
ther optimize the conversion reaction [39]. Primers were
designed using the Sequenom EpiDesigner BETA soft-
ware (www.epidesigner.com), taking into account ampli-
con coverage, number of CpGs, fragment size and
number of nucleotide repeats in the primer sequence
(Additional file 1: Table S7). PCR steps were performed
in triplicate for each DNA sample and a standard devi-
ation between replicates was mostly <10 %. When tripli-
cate measurements had a SD >10 % or when only one of
the triplicates was available, data for that sample were
excluded. The mean of three values was used for further
analyses. The EpiTYPER analysis method reports CpG
methylation values as percentage. Statistical analyses to
quantify DNA methylation differences were performed
using the Prism 6 software (GraphPad Software Inc., San
Diego). DNA samples from PHP patients were consid-
ered epimutated if the methylation value for an
imprinted DMR was outside two and three standard de-
viations determined from the control samples. A two-
tailed T test was used to assess differences in mean
DNA methylation levels between cohorts for the overall
amplicon considered as methylation average and for
each CpG unit within this amplicon separately.
GNAS molecular analysis
Genomic DNA was isolated from leukocytes. Genotype
for the GNAS exon 5 SNP (rs7121) at codon 131 was
determined by PCR with the forward primer 5′-
ttggtagcgccctcccaggc-3′ and the reverse primer 5′-
catgttcctatatggacactg-3′. After denaturation at 95 °C,
40 cycles of DNA amplification were performed using
Taq PCR Mastermix at 95 °C for 30 s, 58 °C for 60 s,
and 72 °C for 60 s. The PCR products were digested
using the restriction enzyme FokI and analyzed on a 2 %
agarose gel. Only samples heterozygous at FokI poly-
morphism were selected. One patient and one control
were heterozygous. Total RNA was extracted from plate-
lets using TRIzol (Invitrogen) reagent, according to the
manufacturer’s protocol. The GNAS gene was amplified
from platelet RNA to check expression of XL.
Additional files
Additional file 1: This contains additional files for Tables S1-S7.
Additional file 2: Detailed schematic representation of the human
GNAS-AS region.
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